10.09.2025 13:23
Danish pharmaceutical company Novo Nordisk, which has 78,400 employees worldwide, announced that it will lay off 9,000 people as part of its restructuring process. Last year, Novo Nordisk was briefly the most valuable publicly traded company in Europe and has decided to redirect its resources towards growth opportunities in the fields of diabetes and obesity.
Danish pharmaceutical company Novo Nordisk, which employs 78,400 people worldwide, announced that it plans to lay off 9,000 employees as part of a restructuring process.
In a statement from Novo Nordisk, it was noted that the company would undergo restructuring to simplify its structure, accelerate decision-making processes, and direct resources towards growth opportunities in diabetes and obesity. The statement indicated that approximately 9,000 employees are expected to be laid off as part of the restructuring, with 5,000 of the layoffs anticipated to occur at the company's headquarters in Denmark.
78,400 EMPLOYEES WORLDWIDE
This layoff plan corresponds to about 11.5% of the company's total workforce. Novo Nordisk employs 78,400 people worldwide. Last year, Novo Nordisk briefly became the most valuable publicly traded company in Europe and expects the cost of the restructuring to be around 8 billion Danish kroner (1.3 billion dollars).
DECLINE IN ANNUAL FINANCIAL EXPECTATIONS
As part of the restructuring plan, Novo Nordisk has also revised its financial expectations for this year. The company expects an adjusted operating profit to increase by 4 to 10 percent, compared to a previous forecast of a 10 to 16 percent increase in operating profit.
As the manufacturer of the drugs Ozempic and Wegovy, Novo Nordisk is facing competitive pressure from its American rival Eli Lilly in the growing diabetes treatment market.